Skip to main content
SpringerLink
Log in

Systemic therapy with calcitonin has positive clinical effects on systemic sclerosis in patients with cutaneous manifestations

  • Therapy
  • Published:
European Journal of Dermatology

Abstract

Background

Calcitonin gene-related peptide (CGRP) is a vasodilatory neuropeptide that plays an important role in the blood vessels of heart and peripheral circulation, a lack of which may cause vasculopathies.

Objective

In this study, the clinical course of disease, as well as the efficacy, side effects, and patient satisfaction of systemic calcitonin therapy in patients with systemic sclerosis (SSc), was evaluated.

Methods

Forty-nine patients received repetitive intravenous calcitonin infusions as first-line treatment. The average number of cycles was 12.2 ± 10.3 over a period of 30 months (each cycle: 100 U/day over 10 days). Clinical examinations, laboratory tests, and organ imaging were performed before the start of, and at regular intervals during therapy in order to evaluate organ manifestations and the clinical course of the disease. In addition, patients’ own experiences of the therapy, side effects, and therapy success were evaluated with standardized questionnaires.

Results

Over the course of the treatment, seven patients experienced improvements in their condition with a considerable reduction in digital ulceration and improved movement (14.3%). Pulmonary function in seven patients improved during the therapy (14.3%). With regards to side effects, nausea (41.7%), headaches (33.3%), fluctuations in blood pressure (29.2%), and flushing (29.2%) were observed. Overall, 45.8% of patients evaluated the therapy as good and 58.3% would undergo further courses of therapy with calcitonin.

Conclusions

Systemic calcitonin treatment seems to have positive clinical effects on SSc and contributes to relieving symptoms, especially in patients with cutaneous manifestations. No severe side effects were reported during this study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sticherling M. Systemic sclerosis–dermatological aspects. Part 1:Pathogenesis, epidemiology, clinical findings. J Dtsch Dermatol Ges 2012; 10: 705–18.

    PubMed  Google Scholar 

  2. Klein–Weigel P, Opitz C, Riemekasten G. Systemic sclerosis–a systematic overview:part 1–disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance. Vasa 2011; 40: 6–19.

    Article  PubMed  Google Scholar 

  3. Sticherling M. Systemic sclerosis–focus on dermatological aspects. Part 2:diagnostics, therapy. J Dtsch Dermatol Ges 2012; 10: 783–91.

    PubMed  Google Scholar 

  4. Young A, Khanna D. Systemic sclerosis:a systematic review on therapeutic management from 2011 to 2014. Curr Opin Rheumatol 2015; 27: 241–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Ciechomska M, van Laar J, O’Reilly S. Current frontiers in systemic sclerosis pathogenesis. Exp Dermatol 2015; 24: 401–6.

    Article  PubMed  Google Scholar 

  6. Chizzolini C. Update on pathophysiology of scleroderma with special reference to immunoinflammatory events. Ann Med 2007; 39: 42–53.

    Article  PubMed  CAS  Google Scholar 

  7. Savarino E, Mei F, Parodi A, et al. Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology (Oxford) 2013; 52: 1095–100.

    Article  CAS  Google Scholar 

  8. McNearney TA, Reveille JD, Fischbach M, et al. Pulmonary involvement in systemic sclerosis:associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007; 57: 318–26.

    Article  PubMed  Google Scholar 

  9. Trang G, Steele R, Baron M, Hudson M. Corticosteroids and the risk of scleroderma renal crisis:a systematic review. Rheumatol Int 2012; 32: 645–53.

    Article  PubMed  CAS  Google Scholar 

  10. Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis:a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66: 754–63.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Turk M, Pope EP. The frequency of scleroderma renal crisis over time:a metaanalysis. J Rheumatol 2016; 43: 1350–5.

    Article  PubMed  Google Scholar 

  12. Knockaert DC. Cardiac involvement in systemic inflammatory diseases. Eur Heart J 2007; 28: 1797–804.

    Article  PubMed  Google Scholar 

  13. Avouac J, Sordet C, Depinay C, et al. Systemic sclerosisassociated Sjögren’s syndrome and relationship to the limited cutaneous subtype:results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum 2006; 54: 2243–9.

    Article  PubMed  CAS  Google Scholar 

  14. Riemekasten G, Sunderkötter C. Vasoactive therapies in systemic sclerosis. Rheumatology (Oxford) 2008; 47: 234–5.

    Google Scholar 

  15. Brueckner CS, Becker MO, Kroencke T, et al. Effect of Sildenafil on digital ulcers in systemic sclerosis–analysis from a single centre pilot study. Ann Rheum Dis 2010; 69: 1475–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. García de la Pe˜na–Lefebvre P, Rodríguez Rubio S, Valero Expósito M, et al. Long–term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology 2008; 47: 464–6.

    Article  Google Scholar 

  17. Herrick AL. Pathogenesis of Raynaud’s phenomenon. Rheumatology 2005; 44: 587–96.

    Article  PubMed  CAS  Google Scholar 

  18. Albrecht HP, Hiller D, Hornstein OP, et al. Microcirculatory functions in systemic sclerosis:additional parameters for therapeutic concepts? J Invest Dermatol 1993; 101: 211–5.

    Article  PubMed  CAS  Google Scholar 

  19. Gevatter M, Keller J, Hornstein OP. The thermoregulatory effectiveness of calcitonin in progressive scleroderma. Z Hautkr 1989; 64: 507–10.

    PubMed  CAS  Google Scholar 

  20. Masi AT, Rodnan GP, Medsger TA, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–90.

    Article  Google Scholar 

  21. Hunzelmann N, Genth E, Krieg T, et al. The registry of the German Network for Systemic Scleroderma:frequency of disease subsets and patterns of organ involvement. Rheumatology 2008; 47: 1185–92.

    Article  PubMed  CAS  Google Scholar 

  22. Lambova SN, Müller–Ladner U. New lines in therapy of Raynaud’s phenomenon. Rheumatol Int 2009; 29: 355–63.

    Article  PubMed  Google Scholar 

  23. Clements PJ, Roth MD, Elashoff R, et al. Scleroderma lung study (SLS):differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 2007; 66: 1641–7.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Khanna D, Clements PJ, Furst DE, et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement:a randomized, double–blind, placebo–controlled trial. Arthritis Rheum 2009; 60: 1102–11.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Apras S, Ertenli I, Ozbalkan Z, et al. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 2003; 48: 2256–61.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Friedrich-Alexander-Universität of Erlangen-Nürnberg, Universitätsklinikum Erlangen, Department of Dermatology, Ulmenweg 18, D-91054, Erlangen, Germany

    Ugur Uslu & Michael Sticherling

  2. LVR-Klinik Bonn, Department of Psychiatry and Psychotherapy, Kaiser-Karl-Ring 20, D-53111, Bonn, Germany

    Laura Streiff

Authors
  1. Ugur Uslu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Streiff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Sticherling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ugur Uslu.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Uslu, U., Streiff, L. & Sticherling, M. Systemic therapy with calcitonin has positive clinical effects on systemic sclerosis in patients with cutaneous manifestations. Eur J Dermatol 28, 364–369 (2018). https://doi.org/10.1684/ejd.2018.3300

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2018.3300

Key words

Search

Navigation